Login to Your Account

BTG Gets 'Sentiment Boost' with Voraxaze Nod in U.S.

By Nuala Moran
BioWorld International Correspondent

Wednesday, January 25, 2012

LONDON – BTG plc is celebrating its first regulatory approval after the FDA gave the nod to Voraxaze, an antidote to the chemotherapeutic methotrexate.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription